Safety and efficacy of a GLP-1 and glucagon receptor dual agonist mazdutide (IBI362) 9 mg and 10 mg in Chinese adults with overweight or obesity: A randomised, placebo-controlled, multiple-ascending-dose phase 1b trial.
Quick Facts
What This Study Found
Participants taking 9 mg of mazdutide lost an average of 11.7% of their body weight, compared to 1.8% in the placebo group.
Key Numbers
How They Did This
The study was a randomized, placebo-controlled trial involving multiple ascending doses of mazdutide over 12 to 16 weeks.
Why This Research Matters
The results indicate that mazdutide could be an effective treatment for obesity, addressing a significant health issue. Its favorable safety profile is also encouraging for future use.
What This Study Doesn't Tell Us
The small sample size and short duration limit the generalizability of the findings.
Trust & Context
- Original Title:
- Safety and efficacy of a GLP-1 and glucagon receptor dual agonist mazdutide (IBI362) 9 mg and 10 mg in Chinese adults with overweight or obesity: A randomised, placebo-controlled, multiple-ascending-dose phase 1b trial.
- Published In:
- EClinicalMedicine, 54, 101691 (2022)
- Authors:
- Ji, Linong(8), Gao, Leili(2), Jiang, Hongwei(4), Yang, Jing, Yu, Lei, Wen, Jie, Cai, Chenghang, Deng, Huan, Feng, Liqi, Song, Baili, Ma, Qingyang, Qian, Lei
- Database ID:
- RPEP-06228
Evidence Hierarchy
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-06228APA
Ji, Linong; Gao, Leili; Jiang, Hongwei; Yang, Jing; Yu, Lei; Wen, Jie; Cai, Chenghang; Deng, Huan; Feng, Liqi; Song, Baili; Ma, Qingyang; Qian, Lei. (2022). Safety and efficacy of a GLP-1 and glucagon receptor dual agonist mazdutide (IBI362) 9 mg and 10 mg in Chinese adults with overweight or obesity: A randomised, placebo-controlled, multiple-ascending-dose phase 1b trial.. EClinicalMedicine, 54, 101691. https://doi.org/10.1016/j.eclinm.2022.101691
MLA
Ji, Linong, et al. "Safety and efficacy of a GLP-1 and glucagon receptor dual agonist mazdutide (IBI362) 9 mg and 10 mg in Chinese adults with overweight or obesity: A randomised, placebo-controlled, multiple-ascending-dose phase 1b trial.." EClinicalMedicine, 2022. https://doi.org/10.1016/j.eclinm.2022.101691
RethinkPeptides
RethinkPeptides Research Database. "Safety and efficacy of a GLP-1 and glucagon receptor dual ag..." RPEP-06228. Retrieved from https://rethinkpeptides.com/research/ji-2022-safety-and-efficacy-of
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.